Drug Profile


Alternative Names: HIV-1 vaccine NYVAC-B; NYVAC poxvirus vector + clade B gag-pol-nef + env immunogen; NYVAC-HIV-B

Latest Information Update: 29 Jan 2009

Price : $50

At a glance

  • Originator EuroVacc Foundation; sanofi pasteur
  • Developer EuroVacc Foundation
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 29 Jan 2009 Phase-I development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top